NasdaqGM:TNGXBiotechs
Tango Therapeutics (TNGX) Zero Q1 Revenue Tests Bullish 56.6% Growth Narrative
Tango Therapeutics (TNGX) just posted its Q1 2026 numbers, with revenue at US$0 million, a reported loss of US$45.5 million and EPS of US$0.32. This sets a stark backdrop for how the rest of the year might look. Over recent quarters, the company has seen revenue move from US$4.1 million in Q4 2024 to US$53.8 million in Q3 2025 and then to US$0 million in Q1 2026. EPS shifted from a loss of US$0.35 in Q4 2024 to EPS of US$0.14 in Q3 2025 before returning to a loss of US$0.32 in the latest...